Bruce Booth

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Council on Foreign Relations, Inc. provides and disseminates ideas on foreign policies to individuals, corporate members, journalists and policy makers. It operates a forum for government officials, students and other interested parties to study and discuss world issues and impact on American foreign policies. The company publishes Foreign Affairs, a magazine that comes out six times a year, along with books and studies by its own scholars. Council on Foreign Relations was founded in 1921 and is headquartered in New York City, NY.

The New York Academy of Medicine (NYAM) is a leading advocate for innovation in public health. The non-profit company is based in New York, NY and has subsidiaries in the United States. For 176 years, NYAM has been at the forefront of promoting bold changes to the systems that perpetuate health inequities and prevent communities from achieving good health. NYAM's work includes innovative research, programs, and policy initiatives that value community input for maximum impact. NYAM's library is one of the most significant historical libraries in medicine and public health in the nation, with an extensive range of recommended resources available.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.

Numerate, Inc. operates as a technology platform company that leverages proprietary algorithms and cloud computing to transform the drug design process. The company was founded by Guido Lanza, Nigel P. Duffy, John Hampton Griffin and Brandon Allgood in 2007 and is headquartered in San Francisco, CA.

Caxton Health Holdings LLC operates as an investment firm. It focus on healthcare sectors, such as healthcare technologies, biopharmaceuticals, drug discovery technology and healthcare information technology. The company is headquartered in New York, NY.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.

Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA.

Penn State Research Foundation provides scientific research services aimed at improving human conditions. The non-profit company is based in University Park, PA.

Prestwick Services LLC is the leading provider of payroll based billing and payment solutions for the workers compensation, property and casualty and benefits industries. Their mission is to create a world class technology and services platform for carriers that want to offer pay-as-clients-go policy and billing solutions through their existing agents. Their management team collectively has over 95 years of experience successfully introducing and supporting technology and associated services to the property and casualty industry. The company is headquartered in Sudbury, Massachusetts with an additional office in Dallas, Texas.

Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Quartet Medicine, Inc. is a biotechnology company that develops treatments for chronic pain and inflammation by restoring tetrahydrobiopterin homeostasis inneuronal and inflammatory cells. Its drug discovery efforts are fully structurally enabled and are focused on demonstrating changes in BH4-related biomarkers that correlate with drug pharmacokinetics and efficacy in preclinical animal models. The company was founded by Kevin Pojasek, Kai Johnsson, and Clifford Woolf in 2013 and is headquartered in Cambridge, MA.

Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts.

Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA.

Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA.

HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA.